Gene: KRAS ×
Source: CLINVAR ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913535
rs121913535
KRAS
G 0.700 CausalMutation CLINVAR Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. 21228335

2011
dbSNP: rs121913535
rs121913535
KRAS
A 0.700 CausalMutation CLINVAR Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. 21228335

2011
dbSNP: rs17851045
rs17851045
KRAS
G 0.700 CausalMutation CLINVAR Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. 21228335

2011
dbSNP: rs17851045
rs17851045
KRAS
A 0.700 CausalMutation CLINVAR Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. 21228335

2011
dbSNP: rs770248150
rs770248150
KRAS
G 0.700 CausalMutation CLINVAR Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. 21228335

2011
dbSNP: rs770248150
rs770248150
KRAS
A 0.700 CausalMutation CLINVAR Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. 21228335

2011
dbSNP: rs1057519725
rs1057519725
KRAS
A 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs1057519725
rs1057519725
KRAS
A 0.700 CausalMutation CLINVAR Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 20921462

2010
dbSNP: rs112445441
rs112445441
KRAS
T 0.700 CausalMutation CLINVAR Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. 20978259

2010
dbSNP: rs112445441
rs112445441
KRAS
G 0.700 CausalMutation CLINVAR Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 20921462

2010
dbSNP: rs112445441
rs112445441
KRAS
G 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs112445441
rs112445441
KRAS
T 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs112445441
rs112445441
KRAS
T 0.700 CausalMutation CLINVAR Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 20921462

2010
dbSNP: rs121913238
rs121913238
KRAS
T 0.700 CausalMutation CLINVAR Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 20921462

2010
dbSNP: rs121913238
rs121913238
KRAS
T 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs121913240
rs121913240
KRAS
C 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs121913240
rs121913240
KRAS
A 0.700 CausalMutation CLINVAR Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 20921462

2010
dbSNP: rs121913240
rs121913240
KRAS
C 0.700 CausalMutation CLINVAR Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 20921462

2010
dbSNP: rs121913240
rs121913240
KRAS
A 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs121913527
rs121913527
KRAS
G 0.700 CausalMutation CLINVAR Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 20921462

2010
dbSNP: rs121913527
rs121913527
KRAS
G 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs121913529
rs121913529
KRAS
A 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs121913529
rs121913529
KRAS
A 0.700 CausalMutation CLINVAR Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 20921462

2010
dbSNP: rs121913529
rs121913529
KRAS
G 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010
dbSNP: rs121913529
rs121913529
KRAS
T 0.700 CausalMutation CLINVAR Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. 20921465

2010